NASDAQ:BeiGene, Ltd.

График котировок BeiGene, Ltd.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 73.84
P/BV 5.48
EV/EBITDA -12.79
EBITDA -1.53
Цена ао 278.92

Основные владельцы

Institutions Объем Доля, %
Baker Bros Advisors LP 13301597 14.59
Hennion & Walsh, Inc 200 0
Advisors Asset Management, Inc. 400 0
Hillhouse Capital Advisors, Ltd. 5472259 6
Boxer Capital LLC 1114188 1.22
Capital Research and Management Company 6065130 6.65
Exchange Traded Concepts, LLC 11163 0.01
Global X Management Company LLC 7694 0.01
Mirae Asset Global Investments (HK) Ltd 94897 0.1
Capital Guardian Trust Company 414413 0.45
HSBC Global Asset Management (HK) Ltd 113713 0.13
Westend Sa 900000 0.99
First Trust Portfolios L.P. 3796 0
Artal Group S A 900000 0.99
Baird Equity Asset Management 24872 0.03
Robert W. Baird & Co. Incorporated 40832 0.04
Capital Group 4738815 5.2
Bellevue Asset Management AG 14400 0.02
Edmond de Rothschild Asset Management (Lux) 59498 0.07
BlackRock Fund Advisors 1473746 1.62
Invesco Ltd (OFI / OppenheimerFunds) 119195 0.13
Invesco Advisers, Inc. 889684 0.98
Baillie Gifford Overseas Limited 209855 0.23

Содержится в ETF

ETF Доля, % Доходность за год, %
Loncar Cancer Immunotherapy ETF 3.92 43.71
Virtus LifeSci Biotech Products ETF 2.49 27.10
Loncar China BioPharma ETF 3.37 36.10
Global X China Biotech Innovation ETF 6.96
KraneShares MSCI All China Health Care Index ETF 3.36 67.19
Global X MSCI China Health Care ETF 6.01 51.72

Похожие компании

Описание BeiGene, Ltd.

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R\u002FR mantle cell lymphoma; Tislelizumab to treat R\u002FR classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; and Hutchison China MediTech Limited. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.